Core Insights - Onconetix, Inc. has completed a private placement of Series D Convertible Preferred Stock and Warrants, raising approximately $12.9 million [1][2] - The financing transaction involved $9.3 million in cash and the remainder used to offset debts [1][3] - The proceeds will be used to settle debts, cover costs related to a terminated business combination, and for working capital [3] Financing Details - The private placement includes shares convertible into 4,362,827 shares of Common Stock and Warrants to purchase the same number of shares [1] - The initial exercise price for the Warrants is set at $3.6896 per share, with anti-dilution adjustments applicable [1] - The Company will seek stockholder approval for the issuance of shares related to the Series D Preferred Stock and Warrants [2] Debt Settlement - Approximately $6.3 million of the financing proceeds were allocated to settle a debt with Veru, Inc., while $2.5 million of debt was converted into Series D Preferred Stock and Warrants [3] - The total debt owed to Veru, Inc. was approximately $8.8 million [3] Company Overview - Onconetix, Inc. is focused on innovative solutions for men's health and oncology, including the Proclarix® diagnostic test for prostate cancer [4] - The Company has acquired Proteomedix, enhancing its product offerings in the oncology space [4]

Core Viewpoint - Onconetix, Inc. and Ocuvex Therapeutics, Inc. have mutually terminated their merger agreement, deciding to pursue independent paths for the benefit of their stakeholders [1][2]. Company Summaries Onconetix, Inc. - Onconetix is a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology [4]. - The company owns Proclarix®, an in vitro diagnostic test for prostate cancer, which is approved for sale in the European Union under the IVDR [4]. Ocuvex Therapeutics, Inc. - Ocuvex is dedicated to advancing ophthalmic science and improving patient outcomes through innovative research and product development [5]. - The company has received its New Jersey state pharmaceutical license and plans to launch Omlonti in the coming weeks [3].

Core Viewpoint - Onconetix, Inc. has announced a licensing agreement with Immunovia AB for the production of antibodies related to pancreatic cancer diagnostics, which is expected to enhance the early detection of pancreatic cancer through the PancreaSure test [1][2]. Group 1: Licensing Agreement Details - Proteomedix AG, a subsidiary of Onconetix, will provide Immunovia with master cells necessary for producing antibodies for three of the five biomarkers in the PancreaSure test [2]. - The agreement includes a license for key intellectual property related to the manufacturing of reagents for measuring these biomarkers, allowing Immunovia to purchase reagents directly from Proteomedix [2]. - Immunovia will pay a total of $700,000 to Proteomedix in 2025 and 2026, along with a 3% royalty on net sales of PancreaSure and other products using the licensed intellectual property from 2026 to 2032 [3]. Group 2: Company Focus and Products - Onconetix is focused on innovative solutions for men's health and oncology, with a particular emphasis on the early detection of prostate cancer through its Proclarix® test [4][5]. - Proclarix® is CE-certified and indicated for prostate cancer diagnosis in patients with specific clinical conditions, demonstrating reliability in detecting clinically significant prostate cancer [6].

Core Viewpoint - Onconetix, Inc. has entered into a definitive merger agreement with Ocuvex Therapeutics, Inc., aiming to enhance its portfolio with ophthalmic therapeutic candidates and create significant value for shareholders [1][2]. Company Overview Onconetix - Onconetix is a commercial stage biotechnology company focused on innovative solutions for men's health and oncology, including the Proclarix® diagnostic test for prostate cancer [6]. Ocuvex - Ocuvex is a privately held biopharmaceutical company specializing in ophthalmic therapeutic candidates, with its lead asset, Omlonti® (omidenepag isopropyl ophthalmic solution) 0.002%, approved by the FDA for ocular hypertension and open-angle glaucoma [8]. Transaction Details - The merger agreement has been approved by the boards of directors of both companies, with Onconetix acquiring all equity interests of Ocuvex [3][4]. - Ocuvex equity holders will receive newly-issued shares of Onconetix common stock equal to 90% of the combined company’s equity interests post-transaction, while Onconetix shareholders will retain 10% [4]. - The board of directors of the combined company will consist of seven directors, with five from Ocuvex and two from Onconetix [5]. Anticipated Timeline - The completion of the proposed transaction is expected in the fourth quarter of 2025, subject to customary conditions including regulatory and stockholder approvals [5].

Core Viewpoint - Onconetix, Inc. and Ocuvex Therapeutics, Inc. have signed a Non-Binding Letter of Intent for a potential business combination, which aims to enhance Onconetix's portfolio beyond oncology and increase shareholder value [1][2]. Company Overview Onconetix, Inc. - Onconetix is a commercial stage biotechnology company focused on men's health and oncology, with products like Proclarix®, an in vitro diagnostic test for prostate cancer, and ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia [4]. Ocuvex Therapeutics, Inc. - Ocuvex is a privately held biopharmaceutical company specializing in ophthalmic therapeutic candidates, formed from the merger of Ocuvex Inc. and Visiox Pharmaceuticals, Inc. in August 2024. Its lead asset, Omlonti®, is an FDA-approved treatment for ocular hypertension and open-angle glaucoma [6]. Transaction Details - The proposed transaction will involve Onconetix acquiring all equity interests of Ocuvex in exchange for newly issued shares of Onconetix, with pre-closing Ocuvex equity holders expected to own approximately 90% of Onconetix post-transaction [2][3]. - The Letter of Intent indicates mutual interest but is subject to due diligence, financing, and regulatory approvals, with no assurance that a definitive agreement will be executed [3].